

Global Human Recombinant Insulin Market Growth 2023-2029

<https://marketpublishers.com/r/GD5B70748641EN.html>

Date: February 2023

Pages: 108

Price: US\$ 3,660.00 (Single User License)

ID: GD5B70748641EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver. Recombinant human insulin has a significant advantage over insulin from other animal sources. Patients can better absorb human insulin. It is also easier to manage allergies related to insulin intake.

LPI (LP Information)' newest research report, the "Human Recombinant Insulin Industry Forecast" looks at past sales and reviews total world Human Recombinant Insulin sales in 2022, providing a comprehensive analysis by region and market sector of projected Human Recombinant Insulin sales for 2023 through 2029. With Human Recombinant Insulin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Human Recombinant Insulin industry.

This Insight Report provides a comprehensive analysis of the global Human Recombinant Insulin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Recombinant Insulin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Human Recombinant Insulin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Recombinant Insulin and breaks down the forecast by type, by application, geography, and market size to highlight emerging

pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Recombinant Insulin.

The global Human Recombinant Insulin market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Human Recombinant Insulin is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Human Recombinant Insulin is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Human Recombinant Insulin is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Human Recombinant Insulin players cover Novo Nordisk, Eli Lilly and Company, Sanofi, Julphar Gulf Pharmaceutical Industries, Bioton, Gan & Lee Pharmaceuticals, Zhuhai United Laboratories, Biocon and Wanbang Biopharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Recombinant Insulin market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Rapid-Acting Human Insulin

Regular (Short Acting) Insulin

NPH (Intermediate Acting) Insulin

Long-Acting Human Insulin

Premixed Human Insulins Insulin

Segmentation by application

Hospital

Retail Pharmacy

Online Pharmacies

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Novo Nordisk

Eli Lilly and Company

Sanofi

Julphar Gulf Pharmaceutical Industries

Bioton

Gan & Lee Pharmaceuticals

Zhuhai United Laboratories

Biocon

Wanbang Biopharmaceuticals

Dongbao Enterprise Group

PeproTech

Key Questions Addressed in this Report

What is the 10-year outlook for the global Human Recombinant Insulin market?

What factors are driving Human Recombinant Insulin market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Human Recombinant Insulin market opportunities vary by end market size?

How does Human Recombinant Insulin break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Human Recombinant Insulin Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Human Recombinant Insulin by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Human Recombinant Insulin by Country/Region, 2018, 2022 & 2029
- 2.2 Human Recombinant Insulin Segment by Type
 - 2.2.1 Rapid-Acting Human Insulin
 - 2.2.2 Regular (Short Acting) Insulin
 - 2.2.3 NPH (Intermediate Acting) Insulin
 - 2.2.4 Long-Acting Human Insulin
 - 2.2.5 Premixed Human Insulins Insulin
- 2.3 Human Recombinant Insulin Sales by Type
 - 2.3.1 Global Human Recombinant Insulin Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Human Recombinant Insulin Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Human Recombinant Insulin Sale Price by Type (2018-2023)
- 2.4 Human Recombinant Insulin Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Retail Pharmacy
 - 2.4.3 Online Pharmacies
 - 2.4.4 Other
- 2.5 Human Recombinant Insulin Sales by Application
 - 2.5.1 Global Human Recombinant Insulin Sale Market Share by Application

(2018-2023)

2.5.2 Global Human Recombinant Insulin Revenue and Market Share by Application

(2018-2023)

2.5.3 Global Human Recombinant Insulin Sale Price by Application (2018-2023)

3 GLOBAL HUMAN RECOMBINANT INSULIN BY COMPANY

3.1 Global Human Recombinant Insulin Breakdown Data by Company

3.1.1 Global Human Recombinant Insulin Annual Sales by Company (2018-2023)

3.1.2 Global Human Recombinant Insulin Sales Market Share by Company

(2018-2023)

3.2 Global Human Recombinant Insulin Annual Revenue by Company (2018-2023)

3.2.1 Global Human Recombinant Insulin Revenue by Company (2018-2023)

3.2.2 Global Human Recombinant Insulin Revenue Market Share by Company

(2018-2023)

3.3 Global Human Recombinant Insulin Sale Price by Company

3.4 Key Manufacturers Human Recombinant Insulin Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Human Recombinant Insulin Product Location Distribution

3.4.2 Players Human Recombinant Insulin Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR HUMAN RECOMBINANT INSULIN BY GEOGRAPHIC REGION

4.1 World Historic Human Recombinant Insulin Market Size by Geographic Region (2018-2023)

4.1.1 Global Human Recombinant Insulin Annual Sales by Geographic Region

(2018-2023)

4.1.2 Global Human Recombinant Insulin Annual Revenue by Geographic Region

(2018-2023)

4.2 World Historic Human Recombinant Insulin Market Size by Country/Region (2018-2023)

4.2.1 Global Human Recombinant Insulin Annual Sales by Country/Region

(2018-2023)

4.2.2 Global Human Recombinant Insulin Annual Revenue by Country/Region (2018-2023)

4.3 Americas Human Recombinant Insulin Sales Growth

4.4 APAC Human Recombinant Insulin Sales Growth

4.5 Europe Human Recombinant Insulin Sales Growth

4.6 Middle East & Africa Human Recombinant Insulin Sales Growth

5 AMERICAS

5.1 Americas Human Recombinant Insulin Sales by Country

5.1.1 Americas Human Recombinant Insulin Sales by Country (2018-2023)

5.1.2 Americas Human Recombinant Insulin Revenue by Country (2018-2023)

5.2 Americas Human Recombinant Insulin Sales by Type

5.3 Americas Human Recombinant Insulin Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Human Recombinant Insulin Sales by Region

6.1.1 APAC Human Recombinant Insulin Sales by Region (2018-2023)

6.1.2 APAC Human Recombinant Insulin Revenue by Region (2018-2023)

6.2 APAC Human Recombinant Insulin Sales by Type

6.3 APAC Human Recombinant Insulin Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Human Recombinant Insulin by Country

7.1.1 Europe Human Recombinant Insulin Sales by Country (2018-2023)

7.1.2 Europe Human Recombinant Insulin Revenue by Country (2018-2023)

- 7.2 Europe Human Recombinant Insulin Sales by Type
- 7.3 Europe Human Recombinant Insulin Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Human Recombinant Insulin by Country
 - 8.1.1 Middle East & Africa Human Recombinant Insulin Sales by Country (2018-2023)
 - 8.1.2 Middle East & Africa Human Recombinant Insulin Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Human Recombinant Insulin Sales by Type
- 8.3 Middle East & Africa Human Recombinant Insulin Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Human Recombinant Insulin
- 10.3 Manufacturing Process Analysis of Human Recombinant Insulin
- 10.4 Industry Chain Structure of Human Recombinant Insulin

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels

- 11.1.2 Indirect Channels
- 11.2 Human Recombinant Insulin Distributors
- 11.3 Human Recombinant Insulin Customer

12 WORLD FORECAST REVIEW FOR HUMAN RECOMBINANT INSULIN BY GEOGRAPHIC REGION

- 12.1 Global Human Recombinant Insulin Market Size Forecast by Region
 - 12.1.1 Global Human Recombinant Insulin Forecast by Region (2024-2029)
 - 12.1.2 Global Human Recombinant Insulin Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Human Recombinant Insulin Forecast by Type
- 12.7 Global Human Recombinant Insulin Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 Novo Nordisk
 - 13.1.1 Novo Nordisk Company Information
 - 13.1.2 Novo Nordisk Human Recombinant Insulin Product Portfolios and Specifications
 - 13.1.3 Novo Nordisk Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.1.4 Novo Nordisk Main Business Overview
 - 13.1.5 Novo Nordisk Latest Developments
- 13.2 Eli Lilly and Company
 - 13.2.1 Eli Lilly and Company Company Information
 - 13.2.2 Eli Lilly and Company Human Recombinant Insulin Product Portfolios and Specifications
 - 13.2.3 Eli Lilly and Company Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.2.4 Eli Lilly and Company Main Business Overview
 - 13.2.5 Eli Lilly and Company Latest Developments
- 13.3 Sanofi
 - 13.3.1 Sanofi Company Information
 - 13.3.2 Sanofi Human Recombinant Insulin Product Portfolios and Specifications

13.3.3 Sanofi Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Sanofi Main Business Overview

13.3.5 Sanofi Latest Developments

13.4 Julphar Gulf Pharmaceutical Industries

13.4.1 Julphar Gulf Pharmaceutical Industries Company Information

13.4.2 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Product Portfolios and Specifications

13.4.3 Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Julphar Gulf Pharmaceutical Industries Main Business Overview

13.4.5 Julphar Gulf Pharmaceutical Industries Latest Developments

13.5 Bioton

13.5.1 Bioton Company Information

13.5.2 Bioton Human Recombinant Insulin Product Portfolios and Specifications

13.5.3 Bioton Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Bioton Main Business Overview

13.5.5 Bioton Latest Developments

13.6 Gan & Lee Pharmaceuticals

13.6.1 Gan & Lee Pharmaceuticals Company Information

13.6.2 Gan & Lee Pharmaceuticals Human Recombinant Insulin Product Portfolios and Specifications

13.6.3 Gan & Lee Pharmaceuticals Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Gan & Lee Pharmaceuticals Main Business Overview

13.6.5 Gan & Lee Pharmaceuticals Latest Developments

13.7 Zhuhai United Laboratories

13.7.1 Zhuhai United Laboratories Company Information

13.7.2 Zhuhai United Laboratories Human Recombinant Insulin Product Portfolios and Specifications

13.7.3 Zhuhai United Laboratories Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Zhuhai United Laboratories Main Business Overview

13.7.5 Zhuhai United Laboratories Latest Developments

13.8 Biocon

13.8.1 Biocon Company Information

13.8.2 Biocon Human Recombinant Insulin Product Portfolios and Specifications

13.8.3 Biocon Human Recombinant Insulin Sales, Revenue, Price and Gross Margin

(2018-2023)

13.8.4 Biocon Main Business Overview

13.8.5 Biocon Latest Developments

13.9 Wanbang Biopharmaceuticals

13.9.1 Wanbang Biopharmaceuticals Company Information

13.9.2 Wanbang Biopharmaceuticals Human Recombinant Insulin Product Portfolios and Specifications

13.9.3 Wanbang Biopharmaceuticals Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.9.4 Wanbang Biopharmaceuticals Main Business Overview

13.9.5 Wanbang Biopharmaceuticals Latest Developments

13.10 Dongbao Enterprise Group

13.10.1 Dongbao Enterprise Group Company Information

13.10.2 Dongbao Enterprise Group Human Recombinant Insulin Product Portfolios and Specifications

13.10.3 Dongbao Enterprise Group Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.10.4 Dongbao Enterprise Group Main Business Overview

13.10.5 Dongbao Enterprise Group Latest Developments

13.11 PeproTech

13.11.1 PeproTech Company Information

13.11.2 PeproTech Human Recombinant Insulin Product Portfolios and Specifications

13.11.3 PeproTech Human Recombinant Insulin Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 PeproTech Main Business Overview

13.11.5 PeproTech Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Human Recombinant Insulin Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Human Recombinant Insulin Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Rapid-Acting Human Insulin

Table 4. Major Players of Regular (Short Acting) Insulin

Table 5. Major Players of NPH (Intermediate Acting) Insulin

Table 6. Major Players of Long-Acting Human Insulin

Table 7. Major Players of Premixed Human Insulins Insulin

Table 8. Global Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)

Table 9. Global Human Recombinant Insulin Sales Market Share by Type (2018-2023)

Table 10. Global Human Recombinant Insulin Revenue by Type (2018-2023) & (\$ million)

Table 11. Global Human Recombinant Insulin Revenue Market Share by Type (2018-2023)

Table 12. Global Human Recombinant Insulin Sale Price by Type (2018-2023) & (USD/Litre)

Table 13. Global Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)

Table 14. Global Human Recombinant Insulin Sales Market Share by Application (2018-2023)

Table 15. Global Human Recombinant Insulin Revenue by Application (2018-2023)

Table 16. Global Human Recombinant Insulin Revenue Market Share by Application (2018-2023)

Table 17. Global Human Recombinant Insulin Sale Price by Application (2018-2023) & (USD/Litre)

Table 18. Global Human Recombinant Insulin Sales by Company (2018-2023) & (K Litre)

Table 19. Global Human Recombinant Insulin Sales Market Share by Company (2018-2023)

Table 20. Global Human Recombinant Insulin Revenue by Company (2018-2023) (\$ Millions)

Table 21. Global Human Recombinant Insulin Revenue Market Share by Company (2018-2023)

Table 22. Global Human Recombinant Insulin Sale Price by Company (2018-2023) &

(USD/Litre)

Table 23. Key Manufacturers Human Recombinant Insulin Producing Area Distribution and Sales Area

Table 24. Players Human Recombinant Insulin Products Offered

Table 25. Human Recombinant Insulin Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 26. New Products and Potential Entrants

Table 27. Mergers & Acquisitions, Expansion

Table 28. Global Human Recombinant Insulin Sales by Geographic Region (2018-2023) & (K Litre)

Table 29. Global Human Recombinant Insulin Sales Market Share Geographic Region (2018-2023)

Table 30. Global Human Recombinant Insulin Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 31. Global Human Recombinant Insulin Revenue Market Share by Geographic Region (2018-2023)

Table 32. Global Human Recombinant Insulin Sales by Country/Region (2018-2023) & (K Litre)

Table 33. Global Human Recombinant Insulin Sales Market Share by Country/Region (2018-2023)

Table 34. Global Human Recombinant Insulin Revenue by Country/Region (2018-2023) & (\$ millions)

Table 35. Global Human Recombinant Insulin Revenue Market Share by Country/Region (2018-2023)

Table 36. Americas Human Recombinant Insulin Sales by Country (2018-2023) & (K Litre)

Table 37. Americas Human Recombinant Insulin Sales Market Share by Country (2018-2023)

Table 38. Americas Human Recombinant Insulin Revenue by Country (2018-2023) & (\$ Millions)

Table 39. Americas Human Recombinant Insulin Revenue Market Share by Country (2018-2023)

Table 40. Americas Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)

Table 41. Americas Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)

Table 42. APAC Human Recombinant Insulin Sales by Region (2018-2023) & (K Litre)

Table 43. APAC Human Recombinant Insulin Sales Market Share by Region (2018-2023)

Table 44. APAC Human Recombinant Insulin Revenue by Region (2018-2023) & (\$

Millions)

Table 45. APAC Human Recombinant Insulin Revenue Market Share by Region (2018-2023)

Table 46. APAC Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)

Table 47. APAC Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)

Table 48. Europe Human Recombinant Insulin Sales by Country (2018-2023) & (K Litre)

Table 49. Europe Human Recombinant Insulin Sales Market Share by Country (2018-2023)

Table 50. Europe Human Recombinant Insulin Revenue by Country (2018-2023) & (\$ Millions)

Table 51. Europe Human Recombinant Insulin Revenue Market Share by Country (2018-2023)

Table 52. Europe Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)

Table 53. Europe Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)

Table 54. Middle East & Africa Human Recombinant Insulin Sales by Country (2018-2023) & (K Litre)

Table 55. Middle East & Africa Human Recombinant Insulin Sales Market Share by Country (2018-2023)

Table 56. Middle East & Africa Human Recombinant Insulin Revenue by Country (2018-2023) & (\$ Millions)

Table 57. Middle East & Africa Human Recombinant Insulin Revenue Market Share by Country (2018-2023)

Table 58. Middle East & Africa Human Recombinant Insulin Sales by Type (2018-2023) & (K Litre)

Table 59. Middle East & Africa Human Recombinant Insulin Sales by Application (2018-2023) & (K Litre)

Table 60. Key Market Drivers & Growth Opportunities of Human Recombinant Insulin

Table 61. Key Market Challenges & Risks of Human Recombinant Insulin

Table 62. Key Industry Trends of Human Recombinant Insulin

Table 63. Human Recombinant Insulin Raw Material

Table 64. Key Suppliers of Raw Materials

Table 65. Human Recombinant Insulin Distributors List

Table 66. Human Recombinant Insulin Customer List

Table 67. Global Human Recombinant Insulin Sales Forecast by Region (2024-2029) & (K Litre)

Table 68. Global Human Recombinant Insulin Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 69. Americas Human Recombinant Insulin Sales Forecast by Country (2024-2029) & (K Litre)
Table 70. Americas Human Recombinant Insulin Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 71. APAC Human Recombinant Insulin Sales Forecast by Region (2024-2029) & (K Litre)
Table 72. APAC Human Recombinant Insulin Revenue Forecast by Region (2024-2029) & (\$ millions)
Table 73. Europe Human Recombinant Insulin Sales Forecast by Country (2024-2029) & (K Litre)
Table 74. Europe Human Recombinant Insulin Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 75. Middle East & Africa Human Recombinant Insulin Sales Forecast by Country (2024-2029) & (K Litre)
Table 76. Middle East & Africa Human Recombinant Insulin Revenue Forecast by Country (2024-2029) & (\$ millions)
Table 77. Global Human Recombinant Insulin Sales Forecast by Type (2024-2029) & (K Litre)
Table 78. Global Human Recombinant Insulin Revenue Forecast by Type (2024-2029) & (\$ Millions)
Table 79. Global Human Recombinant Insulin Sales Forecast by Application (2024-2029) & (K Litre)
Table 80. Global Human Recombinant Insulin Revenue Forecast by Application (2024-2029) & (\$ Millions)
Table 81. Novo Nordisk Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 82. Novo Nordisk Human Recombinant Insulin Product Portfolios and Specifications
Table 83. Novo Nordisk Human Recombinant Insulin Sales (K Litre), Revenue (\$ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 84. Novo Nordisk Main Business
Table 85. Novo Nordisk Latest Developments
Table 86. Eli Lilly and Company Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 87. Eli Lilly and Company Human Recombinant Insulin Product Portfolios and Specifications
Table 88. Eli Lilly and Company Human Recombinant Insulin Sales (K Litre), Revenue (\$ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 89. Eli Lilly and Company Main Business

Table 90. Eli Lilly and Company Latest Developments
Table 91. Sanofi Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 92. Sanofi Human Recombinant Insulin Product Portfolios and Specifications
Table 93. Sanofi Human Recombinant Insulin Sales (K Litre), Revenue (\$ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 94. Sanofi Main Business
Table 95. Sanofi Latest Developments
Table 96. Julphar Gulf Pharmaceutical Industries Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 97. Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Product Portfolios and Specifications
Table 98. Julphar Gulf Pharmaceutical Industries Human Recombinant Insulin Sales (K Litre), Revenue (\$ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 99. Julphar Gulf Pharmaceutical Industries Main Business
Table 100. Julphar Gulf Pharmaceutical Industries Latest Developments
Table 101. Bioton Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 102. Bioton Human Recombinant Insulin Product Portfolios and Specifications
Table 103. Bioton Human Recombinant Insulin Sales (K Litre), Revenue (\$ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 104. Bioton Main Business
Table 105. Bioton Latest Developments
Table 106. Gan & Lee Pharmaceuticals Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 107. Gan & Lee Pharmaceuticals Human Recombinant Insulin Product Portfolios and Specifications
Table 108. Gan & Lee Pharmaceuticals Human Recombinant Insulin Sales (K Litre), Revenue (\$ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 109. Gan & Lee Pharmaceuticals Main Business
Table 110. Gan & Lee Pharmaceuticals Latest Developments
Table 111. Zhuhai United Laboratories Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors
Table 112. Zhuhai United Laboratories Human Recombinant Insulin Product Portfolios and Specifications
Table 113. Zhuhai United Laboratories Human Recombinant Insulin Sales (K Litre), Revenue (\$ Million), Price (USD/Litre) and Gross Margin (2018-2023)
Table 114. Zhuhai United Laboratories Main Business
Table 115. Zhuhai United Laboratories Latest Developments

Table 116. Biocon Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors

Table 117. Biocon Human Recombinant Insulin Product Portfolios and Specifications

Table 118. Biocon Human Recombinant Insulin Sales (K Litre), Revenue (\$ Million), Price (USD/Litre) and Gross Margin (2018-2023)

Table 119. Biocon Main Business

Table 120. Biocon Latest Developments

Table 121. Wanbang Biopharmaceuticals Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors

Table 122. Wanbang Biopharmaceuticals Human Recombinant Insulin Product Portfolios and Specifications

Table 123. Wanbang Biopharmaceuticals Human Recombinant Insulin Sales (K Litre), Revenue (\$ Million), Price (USD/Litre) and Gross Margin (2018-2023)

Table 124. Wanbang Biopharmaceuticals Main Business

Table 125. Wanbang Biopharmaceuticals Latest Developments

Table 126. Dongbao Enterprise Group Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors

Table 127. Dongbao Enterprise Group Human Recombinant Insulin Product Portfolios and Specifications

Table 128. Dongbao Enterprise Group Human Recombinant Insulin Sales (K Litre), Revenue (\$ Million), Price (USD/Litre) and Gross Margin (2018-2023)

Table 129. Dongbao Enterprise Group Main Business

Table 130. Dongbao Enterprise Group Latest Developments

Table 131. PeproTech Basic Information, Human Recombinant Insulin Manufacturing Base, Sales Area and Its Competitors

Table 132. PeproTech Human Recombinant Insulin Product Portfolios and Specifications

Table 133. PeproTech Human Recombinant Insulin Sales (K Litre), Revenue (\$ Million), Price (USD/Litre) and Gross Margin (2018-2023)

Table 134. PeproTech Main Business

Table 135. PeproTech Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Human Recombinant Insulin
- Figure 2. Human Recombinant Insulin Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Human Recombinant Insulin Sales Growth Rate 2018-2029 (K Litre)
- Figure 7. Global Human Recombinant Insulin Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Human Recombinant Insulin Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Rapid-Acting Human Insulin
- Figure 10. Product Picture of Regular (Short Acting) Insulin
- Figure 11. Product Picture of NPH (Intermediate Acting) Insulin
- Figure 12. Product Picture of Long-Acting Human Insulin
- Figure 13. Product Picture of Premixed Human Insulins Insulin
- Figure 14. Global Human Recombinant Insulin Sales Market Share by Type in 2022
- Figure 15. Global Human Recombinant Insulin Revenue Market Share by Type (2018-2023)
- Figure 16. Human Recombinant Insulin Consumed in Hospital
- Figure 17. Global Human Recombinant Insulin Market: Hospital (2018-2023) & (K Litre)
- Figure 18. Human Recombinant Insulin Consumed in Retail Pharmacy
- Figure 19. Global Human Recombinant Insulin Market: Retail Pharmacy (2018-2023) & (K Litre)
- Figure 20. Human Recombinant Insulin Consumed in Online Pharmacies
- Figure 21. Global Human Recombinant Insulin Market: Online Pharmacies (2018-2023) & (K Litre)
- Figure 22. Human Recombinant Insulin Consumed in Other
- Figure 23. Global Human Recombinant Insulin Market: Other (2018-2023) & (K Litre)
- Figure 24. Global Human Recombinant Insulin Sales Market Share by Application (2022)
- Figure 25. Global Human Recombinant Insulin Revenue Market Share by Application in 2022
- Figure 26. Human Recombinant Insulin Sales Market by Company in 2022 (K Litre)
- Figure 27. Global Human Recombinant Insulin Sales Market Share by Company in 2022

Figure 28. Human Recombinant Insulin Revenue Market by Company in 2022 (\$ Million)

Figure 29. Global Human Recombinant Insulin Revenue Market Share by Company in 2022

Figure 30. Global Human Recombinant Insulin Sales Market Share by Geographic Region (2018-2023)

Figure 31. Global Human Recombinant Insulin Revenue Market Share by Geographic Region in 2022

Figure 32. Americas Human Recombinant Insulin Sales 2018-2023 (K Litre)

Figure 33. Americas Human Recombinant Insulin Revenue 2018-2023 (\$ Millions)

Figure 34. APAC Human Recombinant Insulin Sales 2018-2023 (K Litre)

Figure 35. APAC Human Recombinant Insulin Revenue 2018-2023 (\$ Millions)

Figure 36. Europe Human Recombinant Insulin Sales 2018-2023 (K Litre)

Figure 37. Europe Human Recombinant Insulin Revenue 2018-2023 (\$ Millions)

Figure 38. Middle East & Africa Human Recombinant Insulin Sales 2018-2023 (K Litre)

Figure 39. Middle East & Africa Human Recombinant Insulin Revenue 2018-2023 (\$ Millions)

Figure 40. Americas Human Recombinant Insulin Sales Market Share by Country in 2022

Figure 41. Americas Human Recombinant Insulin Revenue Market Share by Country in 2022

Figure 42. Americas Human Recombinant Insulin Sales Market Share by Type (2018-2023)

Figure 43. Americas Human Recombinant Insulin Sales Market Share by Application (2018-2023)

Figure 44. United States Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 45. Canada Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 46. Mexico Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 47. Brazil Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 48. APAC Human Recombinant Insulin Sales Market Share by Region in 2022

Figure 49. APAC Human Recombinant Insulin Revenue Market Share by Regions in 2022

Figure 50. APAC Human Recombinant Insulin Sales Market Share by Type (2018-2023)

Figure 51. APAC Human Recombinant Insulin Sales Market Share by Application (2018-2023)

Figure 52. China Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Japan Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 54. South Korea Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 55. Southeast Asia Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 56. India Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 57. Australia Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 58. China Taiwan Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 59. Europe Human Recombinant Insulin Sales Market Share by Country in 2022

Figure 60. Europe Human Recombinant Insulin Revenue Market Share by Country in 2022

Figure 61. Europe Human Recombinant Insulin Sales Market Share by Type (2018-2023)

Figure 62. Europe Human Recombinant Insulin Sales Market Share by Application (2018-2023)

Figure 63. Germany Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 64. France Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 65. UK Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 66. Italy Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 67. Russia Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 68. Middle East & Africa Human Recombinant Insulin Sales Market Share by Country in 2022

Figure 69. Middle East & Africa Human Recombinant Insulin Revenue Market Share by Country in 2022

Figure 70. Middle East & Africa Human Recombinant Insulin Sales Market Share by Type (2018-2023)

Figure 71. Middle East & Africa Human Recombinant Insulin Sales Market Share by Application (2018-2023)

Figure 72. Egypt Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 73. South Africa Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 74. Israel Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 75. Turkey Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 76. GCC Country Human Recombinant Insulin Revenue Growth 2018-2023 (\$ Millions)

Figure 77. Manufacturing Cost Structure Analysis of Human Recombinant Insulin in 2022

Figure 78. Manufacturing Process Analysis of Human Recombinant Insulin

Figure 79. Industry Chain Structure of Human Recombinant Insulin

Figure 80. Channels of Distribution

Figure 81. Global Human Recombinant Insulin Sales Market Forecast by Region (2024-2029)

Figure 82. Global Human Recombinant Insulin Revenue Market Share Forecast by Region (2024-2029)

Figure 83. Global Human Recombinant Insulin Sales Market Share Forecast by Type (2024-2029)

Figure 84. Global Human Recombinant Insulin Revenue Market Share Forecast by Type (2024-2029)

Figure 85. Global Human Recombinant Insulin Sales Market Share Forecast by Application (2024-2029)

Figure 86. Global Human Recombinant Insulin Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Human Recombinant Insulin Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GD5B70748641EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD5B70748641EN.html>